CytomX Therapeutics to Announce Q2 2024 Financial Results on August 8, 2024

CytomX Therapeutics, Inc. (Nasdaq: CTMX), based in South San Francisco, California, has announced it will release its financial results for the second quarter on Thursday, August 8, 2024, after the closure of U.S. markets. Following this announcement, CytomX will hold a conference call and webcast at 5:00 p.m. Eastern Time (ET) / 2:00 p.m. Pacific Time (PT). Interested participants can access the live webcast through the Events and Presentations page on CytomX’s website. It is advisable for participants to register at least ten minutes before the conference call begins. Additionally, a replay of the webcast will be available on the company’s website.

CytomX Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, with a specialized focus on oncology. The company aims to develop innovative conditionally activated biologics that target the tumor microenvironment. With its PROBODY® therapeutic platform, CytomX seeks to introduce safer and more effective cancer therapies. 

The company's diverse pipeline includes multiple therapeutic candidates deployed across various treatment modalities, such as antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators like cytokines. The clinical-stage pipeline features several key candidates: CX-904, CX-2051, and CX-801.

CX-904 is a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. This candidate is conditionally activated and aims to engage T cells directly with tumor cells. CX-904 is being developed in a global co-development partnership with Amgen.

CX-2051 is another conditionally activated therapeutic, specifically an ADC directed toward the epithelial cell adhesion molecule (EpCAM). This candidate has the potential for widespread application across various EpCAM-expressing epithelial cancers. CX-2051 was initially discovered in collaboration with Immunogen, which is now part of AbbVie.

CX-801 is an interferon alpha-2b PROBODY® cytokine, designed to have broad applicability in both traditionally immune-responsive (hot) tumors and those less responsive to immunotherapy (cold tumors).

CytomX has also established strategic partnerships with several leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. These collaborations aim to further the development and potential commercialization of CytomX’s innovative cancer therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!